The association between neurological diseases,
malignancies and cardiovascular comorbidities
among patients with bullous pemphigoid:
Case-control study in a specialized Polish center

Kalińska-Bienias, Agnieszka; Kowalczyk, Emilia; Jagielski, Paweł; Bienias, Piotr; Kowaléwski, Cezary; Woźniak, Katarzyna

doi:10.17219/acem/90922

Cited by 25 publications

(24 citation statements)

References 28 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It usually develops on areas of skin that often flex, such as the lower abdomen, upper thighs, or armpits. The clinical manifestations of BP include tense bullae, urticarial skin lesions and pruritus, oral mucous membrane erosions that may be present in 10-20% of patients [1][2][3]. In some patients, eczema-like erythema may proceed for months or even for many years as a prodromal phase before BP develops [1].…”

Section: Introductionmentioning

confidence: 99%

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System

Huang

Liu

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: The world's first Diabetes Medications (Insulin) was marketed in October 1923. Some studies suggested the association of diabetes medications with Bullous Pemphigoid (BP), especially the Dipeptidyl Peptidase 4 (DPP-4) inhibitors. The study aims to detect an association between diabetes medications (focusing on DPP-4 inhibitors) and bullous pemphigoid based on FDA Adverse Event Reporting System (FAERS). Methods: All spontaneous reports of diabetes medications inhibitors-related BP recorded in the FAERS between March 2004 and August 2020 were included in the present study. Disproportionality analysis was performed to find the signal between diabetes medications and BP. The Chi-Squared with Yates' correction (χ 2 Yates), proportional reporting ratio (PRR) and the lower limit of the 95% confidence interval of the Reporting Odds Ratio (ROR025) were calculated as a measure. A signal was detected when ROR025 > 1, PRR > 2, χ 2 Yates > 4 and at least 3 cases. Results: There were 3770 reports for BP in FAERS. The strongest signal for diabetes medications-BP association were DDP-4 inhibitors (

show abstract

Section: Introductionmentioning

confidence: 99%

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System

Huang

Liu

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Literature data about the association of BP with malignancies are controversial (29): the open question is whether there is an association between these pathologies and whether they share a common pathophysiologic mechanism. Among the different theories, one of the most accredited suggests that antibodies against tumor-specific antigens cross-react with antigens of epithelial basement membrane zone (BMZ) (30).…”

Section: Discussionmentioning

confidence: 99%

A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases

Ferranti

Gobbo

Cicogna

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: Autoimmune bullous diseases (AIBDs) of the skin and mucosae include a heterogeneous group of chronic diseases, which could be associated with various comorbidities. The purpose of this study was to evaluate the comorbidity profiles of patients affected by AIBDs, who referred to the Dermatological Clinic of Padua from December 2015 to June 2018. Patients and Methods: A monocentric retrospective observational study was conducted on 157 patients with diagnosis of AIBDs. Patients' comorbidities were investigated during the periodic visits of follow-up and through the analysis of computerized medical records. Results: Among the 157 patients, 40 (25.5%) were diagnosed with PV, 15 (9.6%) with PF, and 102 (64.9%) with BP. Nine different comorbidities were observed, but only two of these were statistically significantly associated with BP: type 2 diabetes (p=0.0142) and neuropsychiatric disorders (p=0.015). Conclusion: BP is statistically significantly associated with type 2 diabetes mellitus and neuropsychiatric diseases. The correlation with neuropsychiatric pathologies is interesting for the possible bidirectional role in their etiology. The association with type 2 diabetes mellitus could suggest more caution in the administration of systemic corticosteroids, especially in elderly patients.

show abstract

“…18 Association with neurological conditions and psychiatric disorders have been observed also in other epidemiological studies. [19][20][21] Link with psychiatric conditions is not consistently found in every series. 19,22 Bastuji-Garin et al observed that patients with BP were more likely to have bipolar disorder (4%) compared with controls.…”

Section: Bullous Pemphigoid and Neurological And Psychiatric Disordersmentioning

confidence: 92%

<p>Depression and Anxiety in Patients with Bullous Pemphigoid: Impact and Management Challenges</p>

Kluger¹,

Pankakoski²,

Panelius³

2020

CCID

View full text Add to dashboard Cite

Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. It is also associated with high mortality and poor prognosis due to advanced age of the patients and coexisting comorbidities. There is a dearth of data in the literature regarding depression and anxiety among those patients. The objective of this brief review is to discuss the intertwining relationship between depression and anxiety with bullous pemphigoid.

show abstract

The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center

Abstract: The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center.

Cited by 25 publications

References 28 publications

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System

A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases

<p>Depression and Anxiety in Patients with Bullous Pemphigoid: Impact and Management Challenges</p>

Contact Info

Product

Resources

About